“When initiating denosumab for osteoporosis treatment, it is recommended to engage in thorough shared decision-making with the patient to ensure they understand the potential risks associated with discontinuing the medication,” senior author Shau-Huai Fu, MD, PhD, Department of Orthopedics, National Taiwan University Hospital Yunlin Branch, Douliu, Taiwan, told Medscape Medical News.
Shau-Huai Fu, MD, PhD,




![[Test]US Original PMAs and Panel-Track Supplements](https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/VQ3UE5JQIZEX7D5Y7CCJ7ELPDA.png)